PrimeC

NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Image
NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Cambridge, Mass. – – October 03, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 03, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its October 03, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Company to appeal delisting threat before Nasdaq Hearings Panel

NeuroSense intends to timely request a hearing before a Nasdaq Hearings Panel under Nasdaq Listing Rule 5800 Series to seek additional time to regain MVLS compliance. A timely hearing request automatically stays any suspension of trading and the filing of a Form 25-NSE with the SEC while the Panel reviews the case. The Panel has discretion to grant an exception of up to 180 days from the October 1 Staff Determination date.

NeuroSense Cuts H1 Costs 28%, Targets Dec. 2026 Canada ALS Filing

Image
NeuroSense Cuts H1 Costs 28%, Targets Dec. 2026 Canada ALS Filing

Cambridge, Mass. – September 26, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.

NeuroSense trims R&D and G&A spending by double digits in H1 2026

Research and development expenses fell 16% to $2,102 thousand from $2,503 thousand, driven by lower subcontractor and consultant costs, partly offset by higher share-based payment expense. General and administrative expenses dropped 38.6% to $1,345 thousand from $2,189 thousand on reduced professional services spending.